ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Aeovian raises $37 million for mTORC1 inhibitors

by Ryan Cross
October 12, 2019 | APPEARED IN VOLUME 97, ISSUE 40

 

San Francisco–based Aeovian Pharmaceuticals has raised $37 million in series A financing to develop a small-molecule drug candidate that inhibits a protein complex called mammalian target of rapamycin complex 1 (mTORC1). Existing mTORC1 inhibitors also target a similar complex, called mTORC2, causing several immune and metabolic side effects. Aeovian’s first program will inhibit mTORC1 to treat a nervous system disease, but the firm later plans antiaging studies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment